Catalog No.
DHB95904
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
T-cell surface antigen T4/Leu-3, T-cell surface glycoprotein CD4, CD4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01730
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ORTHOCLONE OKT4 A, CAS: 156586-90-2
Clone ID
Cedelizumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age, PMID: 28070861
Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study, PMID: 32901983
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis, PMID: 29935327
Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing, PMID: 30860423
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease, PMID: 31646853
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis, PMID: 30830573
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers, PMID: 33340426
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure, PMID: 32981127
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease, PMID: 25996351
Should we use vedolizumab as mono or combo therapy in ulcerative colitis?, PMID: 30060935
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis, PMID: 32062041
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study, PMID: 30518410
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2, PMID: 29471381
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study, PMID: 33345331
A product review of vedolizumab in inflammatory bowel disease, PMID: 30897022
The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor, PMID: 32249966
Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data, PMID: 31747086
Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases, PMID: 29857145
Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease, PMID: 30219028
Vedolizumab for the treatment of Crohn's disease, PMID: 29406811
Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme, PMID: 33210333
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients, PMID: 32080886
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab, PMID: 27252400
Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?, PMID: 31951748
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review, PMID: 31076751
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease, PMID: 29730603
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice, PMID: 31777929
Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study, PMID: 30807613
Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review, PMID: 30468919
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment, PMID: 32441396
Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease, PMID: 30914021
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease, PMID: 29484571
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease, PMID: 29430672
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease, PMID: 31175865
Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease, PMID: 29788272
Long-term Efficacy of Vedolizumab for Ulcerative Colitis, PMID: 27683800
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease, PMID: 32656800
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease, PMID: 31279871
Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease, PMID: 27598742
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab, PMID: 28523450
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis, PMID: 28204866
Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview, PMID: 31064370
Long-term Efficacy of Vedolizumab for Crohn's Disease, PMID: 27683798
The safety of vedolizumab for ulcerative colitis and Crohn's disease, PMID: 26893500
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review, PMID: 32562207
The safety of vedolizumab for the treatment of ulcerative colitis, PMID: 28276855
Vedolizumab as induction and maintenance therapy for Crohn's disease, PMID: 23964933
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis, PMID: 31470005
Long-term safety of vedolizumab for inflammatory bowel disease, PMID: 32876349
Vedolizumab as induction and maintenance therapy for ulcerative colitis, PMID: 23964932
For research use only. Not for human or drug use.
